Loading
Lucence
Lucence offers blood tests that read both tumour DNA and tumour RNA from a single sample to help doctors choose targeted treatments, and is developing a multi-cancer screening test.
Overview
Lucence is a precision diagnostics company with laboratories in Singapore and Palo Alto, California, and an office in Hong Kong. Its AmpliMARK amplicon-based technology enables ultrasensitive detection of cell-free DNA and RNA. The flagship LiquidHALLMARK assay profiles circulating tumour DNA and RNA in one blood draw to identify actionable mutations and fusions in solid tumours, with a cerebrospinal fluid version for central nervous system cancers. LucenceINSIGHT is a multi-cancer early detection (MCED) test the company states screens at 99 percent specificity, and LucenceMONITOR addresses treatment monitoring. Laboratories are CAP-accredited and CLIA-certified. Data on combined ctDNA and ctRNA yield were presented at ASCO 2025, and in March 2026 Lucence, DxD Hub and the National Cancer Centre Singapore launched an S$6 million research collaboration.
Notes
- No funding round could be sourced from primary releases on the company site; stage set to startup provisionally. Founding year not sourced. Cancer and target tags reflect typical LiquidHALLMARK coverage described generically on the site rather than a fetched panel list.
Connected
15Similar pages
- CompanyImagene AI
- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
- CompanyInivata
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- Key paperClinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer
- PersonTakashi Kohno
Shares RET, RNA sequencing & expression profiling, Comprehensive genomic profiling, Non-small-cell lung cancer.
- InstitutionAichi Cancer Center
Shares ALK, EGFR, Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- Key paperProspective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
cancers
fronts
technologies
targets
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
lucence.com · 3
A source that has moved or gone is reported by the weekly link check. /audit/